Displaying drugs 14101 - 14125 of 14836 in total
GDC-0349
GDC-0349 has been used in trials studying the treatment of Non-Hodgkin's Lymphoma, Solid Tumor.
Investigational
IQP-0528
IQP-0528 is under investigation in clinical trial NCT03082690 (ImQuest (IQP) DuoGel Phase 1 Pharmacokinetic Study).
Investigational
AZD3409
AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February 2007 the development of AZD3409 had been discontinued.
Investigational
Matched Description: … Phase I trials were initiated January 2003, and were ongoing as of February 2004. …
Seproxetine
Seproxetine is also known as (S)-norfluoxetine. It is a selective serotonin reuptake inhibitor (SSRI). It is an active metabolite of fluoxetine. Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and the drug was never marketed.
Investigational
Matched Description: … Seproxetine was being investigated by Eli Lilly as an antidepressant but development was never completed and …
Giredestrant
Giredestrant is under investigation in clinical trial NCT06065748 (A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With Er-positive, Her2-negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (Pionera Breast Cancer)).
Investigational
Matched Description: … Giredestrant is under investigation in clinical trial NCT06065748 (A Study to Evaluate Efficacy and Safety …
CRA_1144
Experimental
p-Nitrophenylacetic acid
Experimental
4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
Experimental
N-oxo-2-(phenylsulfonylamino)ethanamide
Experimental
2-(3-NITROPHENYL)ACETIC ACID
Experimental
N-(3-AMINOPROPYL)-2-NITROBENZENAMINE
Experimental
Pumosetrag
Pumosetrag has been used in trials studying Gastroesophageal Reflux Disease.
Investigational
123I-iodometomidate
123I-iodometomidate is under investigation in clinical trial NCT00454103 (Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy).
Investigational
SR 121463
SR 121463 is a nonpeptide aquaretic compound with potent selective antagonism of the vasopressin V2 (V1b) receptor subtype. It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).
Investigational
Matched Description: … It is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion …
Displaying drugs 14101 - 14125 of 14836 in total